Business Wire

Business Reply and Pusterla 1880: Global Digital Transformation in Luxury Packaging with Oracle Cloud

3.10.2025 10:00:00 CEST | Business Wire | Press Release

Share

Business Reply, the Reply company specialized in the implementation of enterprise solutions based on Oracle technologies, supported Pusterla 1880 — an international leader in the luxury packaging sector — in a digital transformation project aimed at standardizing and optimizing financial, logistics, and production processes on a global scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251003867603/en/

With the support of Business Reply, Pusterla 1880 adopted a fully integrated solution on Oracle Cloud, enabling the harmonization of operational workflows on a global scale.

With over 140 years of experience and a continuously expanding presence across Europe, Asia, and the Americas, Pusterla 1880 operates in a sector that demands high standards of customization, quality, and precision. End-to-end supply chain traceability is a strategic element for ensuring full control over the entire production cycle, from the management of raw materials to the delivery of the finished product. The company’s growth and market diversification had led to excessive fragmentation of IT systems, resulting in negative impacts on visibility, coordination, and operational scalability.

With the support of Business Reply, Pusterla 1880 adopted a fully integrated solution on Oracle Cloud, enabling the harmonization of operational workflows on a global scale. The project involved several modules of the Oracle Cloud suite, including ERP Cloud (Financials, Procurement, Order Management, Supply Chain Planning, and Manufacturing), Oracle WMS Cloud, and Oracle Transportation Management (OTM) Cloud. In particular, the introduction of Oracle Transportation Management significantly optimized the management of international logistics flows, enabling more efficient shipment planning, real-time load tracking, and proactive exception management. The centralization of transportation information and the ability to monitor operational KPIs in real time further enhanced collaboration between logistics and production departments, contributing to reduced costs and delays.

“The collaboration with Business Reply and the implementation of Oracle Cloud have allowed us to gain an integrated view of our business units and complete control over our financial and operational processes. The end-to-end system integration has enabled us to manage the entire operational flow — from procurement planning through to logistics and administration — in a smooth and coordinated way, reducing manual activities and automating low-value tasks. This result allows us to support strategic decisions with reliable and shared data.” said Luca Meana, Presidente di Pusterla 1880.

Business Reply, one of the few partners in EMEA to have achieved all Oracle Cloud Service Expertise certifications in the Supply Chain Management area — including Product Lifecycle Management, Supply Chain Planning, Transportation and Global Trade Management, Warehouse Management, Manufacturing, Order Management, and Procurement — accompanied Pusterla 1880 on an end-to-end digital transformation journey, demonstrating its ability to implement high-value solutions on Oracle Cloud to support the evolution of manufacturing companies in dynamic and continuously changing scenarios.

Pusterla 1880
Pusterla 1880 is a leading company in luxury packaging production with a long tradition and a strong commitment to sustainability and innovation. Through continuous research into innovative materials and original technical solutions, Pusterla offers high-quality, customised packaging with a focus on environmental sustainability. www.pusterla1880.com

Business Reply
Business Reply is the Reply group company specialized in the creation of integrated systems based on Oracle application solutions. With over 20 years of experience, Business Reply is a leading provider of ERP and Corporate Governance services. Driven by a strong commitment to Digital Transformation, continuous investments in innovation, research and development, and dedicated training programs for its people, Business Reply was the first Italian Oracle partner to implement projects on Oracle ERP Cloud, OTM Cloud, and Service Cloud platforms. Business Reply supports its clients with in-depth knowledge of business processes — gained through extensive experience across different industries — combined with strong technical expertise in all Oracle application solutions (ERP, CX, Transportation and Supply Chain, PLM, HCM, and Business Intelligence).

Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251003867603/en/

Contacts

Media

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Irene Caia
i.caia@reply.com
Tel. +39 02 535761

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye